Loading...
•
Sep 28, 2025
Johnson & Johnson Q3 2025 Earnings Report
Johnson & Johnson reported strong third-quarter results with higher net income and raised its full-year sales guidance.
Key Takeaways
Johnson & Johnson saw a sharp rise in net income and strong sales growth, particularly across its Innovative Medicine and MedTech segments, leading to an upward revision of its 2025 full-year sales guidance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Johnson & Johnson raised its full-year 2025 sales guidance and reaffirmed adjusted EPS expectations, despite higher tax costs.
Positive Outlook
- Full-year sales guidance increased to $93.7B at midpoint
- Adjusted EPS guidance reaffirmed at $10.85
- Continued momentum in Innovative Medicine pipeline
- Strong performance of key products like DARZALEX and TREMFYA
- Positive regulatory updates and approvals including INLEXZO and TREMFYA
Challenges Ahead
- Higher effective tax rate impacting GAAP net earnings
- Decline in IMBRUVICA sales due to competition
- STELARA erosion weighed on immunology growth
- Some impact from divestitures and currency headwinds
- Pressure from restructuring and litigation-related costs
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...